Symbols / GDTC Stock $0.98 +3.08% CytoMed Therapeutics Limited

Healthcare • Biotechnology • Singapore • NCM
GDTC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO
Exch · Country NCM · Singapore
Market Cap 11.60M
Enterprise Value 9.94M
Income -3.98M
Sales 860.85K
FCF (ttm) -2.72M
Book/sh 0.43
Cash/sh 0.18
Employees
Insider 10d
IPO Apr 14, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E -6.53
PEG
P/S 13.47
P/B 2.26
P/C
EV/EBITDA -2.58
EV/Sales 11.55
Quick Ratio 3.14
Current Ratio 5.17
Debt/Eq 7.04
LT Debt/Eq
EPS (ttm) -0.27
EPS next Y -0.15
EPS Growth
Revenue Growth 46.90%
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next)
Earnings (prior)
ROA -29.31%
ROE -50.28%
ROIC
Gross Margin 89.57%
Oper. Margin -5.35%
Profit Margin 0.00%
Shs Outstand 11.83M
Shs Float 3.97M
Insider Own 67.83%
Instit Own 0.49%
Short Float 2.06%
Short Ratio 9.27
Short Interest 71.94K
52W High 3.68
vs 52W High -73.37%
52W Low 0.73
vs 52W Low 34.62%
Beta -0.21
Impl. Vol.
Rel Volume 0.01
Avg Volume 572.66K
Volume 3.67K
Target (mean)
Tgt Median
Tgt Low
Tgt High
# Analysts
Recom None
Prev Close $0.95
Price $0.98
Change 3.08%
About

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.98
Low
High
Mean

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-10-10 reit Benchmark Speculative Buy → Speculative Buy $5
2024-06-11 reit Benchmark Speculative Buy → Speculative Buy $5
2023-12-04 reit Benchmark Speculative Buy → Speculative Buy $5
2023-07-21 init Benchmark — → Speculative Buy $5
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.32
+366.74%
0.07
0.00
0.00
Operating Revenue
0.32
+366.74%
0.07
0.00
0.00
Cost Of Revenue
0.07
+297.13%
0.02
0.00
0.00
Reconciled Cost Of Revenue
0.07
+297.13%
0.02
0.00
0.00
Gross Profit
0.26
+389.49%
0.05
0.00
0.00
Operating Expense
4.50
+41.32%
3.18
-17.17%
3.84
+106.99%
1.86
Research And Development
2.22
+16.13%
1.91
+20.12%
1.59
+4.40%
1.52
Selling General And Administration
1.84
+45.60%
1.27
-1.44%
1.28
+223.37%
0.40
Selling And Marketing Expense
0.05
+128.64%
0.02
-28.60%
0.03
0.00
General And Administrative Expense
1.79
+44.01%
1.24
-0.71%
1.25
+214.98%
0.40
Salaries And Wages
1.32
+112.41%
0.62
+36.37%
0.45
+115.58%
0.21
Other Gand A
0.47
-10.92%
0.53
+2.50%
0.51
+177.98%
0.18
Other Operating Expenses
0.20
+263.66%
-0.12
-114.34%
0.86
+571.33%
-0.18
Total Expenses
4.57
+42.69%
3.20
-16.73%
3.84
+106.99%
1.86
Operating Income
-4.24
-35.49%
-3.13
+18.54%
-3.84
-106.99%
-1.86
EBITDA
-3.57
-64.98%
-2.17
+41.46%
-3.70
-41.67%
-2.61
Normalized EBITDA
-3.71
-50.75%
-2.46
+25.48%
-3.31
-27.86%
-2.59
Reconciled Depreciation
0.40
+19.75%
0.34
-12.01%
0.38
-2.98%
0.39
EBIT
-3.98
-58.92%
-2.50
+38.71%
-4.08
-35.83%
-3.00
Total Unusual Items
0.14
-52.84%
0.30
+175.49%
-0.39
-1407.75%
-0.03
Total Unusual Items Excluding Goodwill
0.14
-52.84%
0.30
+175.49%
-0.39
-1407.75%
-0.03
Special Income Charges
0.29
0.00
0.00
-100.00%
0.00
Impairment Of Capital Assets
0.01
0.00
0.00
Net Income
-3.98
-58.16%
-2.52
+39.11%
-4.13
-31.99%
-3.13
Pretax Income
-4.00
-58.47%
-2.52
+38.98%
-4.13
-32.04%
-3.13
Net Non Operating Interest Income Expense
0.10
-65.36%
0.30
+26.84%
0.23
+290.48%
-0.12
Interest Expense Non Operating
0.02
+2.92%
0.02
-60.39%
0.05
-59.03%
0.13
Net Interest Income
0.10
-65.36%
0.30
+26.84%
0.23
+290.48%
-0.12
Interest Expense
0.02
+2.92%
0.02
-60.39%
0.05
-59.03%
0.13
Interest Income Non Operating
0.12
-61.00%
0.32
+11.18%
0.29
+13525.13%
0.00
Interest Income
0.12
-61.00%
0.32
+11.18%
0.29
+13525.13%
0.00
Other Income Expense
0.14
-54.27%
0.31
+159.40%
-0.52
+54.43%
-1.15
Other Non Operating Income Expenses
0.01
-0.10
+90.94%
-1.09
Gain On Sale Of Security
-0.15
-148.87%
0.30
+175.49%
-0.39
-1391.77%
-0.03
Gain On Sale Of Business
0.29
0.00
0.00
Tax Provision
0.00
0.00
-100.00%
0.00
-60.18%
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-0.07
-1407.75%
-0.00
Net Income Including Noncontrolling Interests
-4.00
-58.47%
-2.52
+38.98%
-4.13
-31.99%
-3.13
Net Income From Continuing Operation Net Minority Interest
-3.98
-58.16%
-2.52
+39.11%
-4.13
-31.99%
-3.13
Net Income From Continuing And Discontinued Operation
-3.98
-58.16%
-2.52
+39.11%
-4.13
-31.99%
-3.13
Net Income Continuous Operations
-4.00
-58.47%
-2.52
+38.98%
-4.13
-31.99%
-3.13
Minority Interests
0.02
+207.55%
0.01
+1784.31%
0.00
+12.76%
0.00
Normalized Income
-4.12
-46.43%
-2.81
+26.05%
-3.81
-22.39%
-3.11
Net Income Common Stockholders
-3.98
-58.16%
-2.52
+39.11%
-4.13
-31.99%
-3.13
Diluted EPS
-0.39
-36.26%
-0.29
Basic EPS
-0.39
-36.26%
-0.29
Basic Average Shares
10.63
-2.83%
10.94
Diluted Average Shares
10.63
-2.83%
10.94
Diluted NI Availto Com Stockholders
-3.98
-58.16%
-2.52
+39.11%
-4.13
-31.99%
-3.13
Amortization
0.03
+138.11%
0.01
+474.17%
0.00
-12.52%
0.00
Amortization Of Intangibles Income Statement
0.03
+138.11%
0.01
+474.17%
0.00
-12.52%
0.00
Depreciation Amortization Depletion Income Statement
0.23
+85.29%
0.12
+17.63%
0.10
-6.88%
0.11
Depreciation And Amortization In Income Statement
0.23
+85.29%
0.12
+17.63%
0.10
-6.88%
0.11
Depreciation Income Statement
0.20
+79.25%
0.11
+7.83%
0.10
-6.76%
0.11
Earnings From Equity Interest
-0.01
-146.43%
0.01
+144.12%
-0.03
+7.00%
-0.03
Gain On Sale Of PPE
0.00
0.00
-100.00%
0.00
Insurance And Claims
0.00
-100.00%
0.09
-66.63%
0.28
0.00
Other Taxes
0.01
+12.60%
0.01
+26.29%
0.01
-5.45%
0.01
Rent And Landing Fees
0.01
+63.83%
0.00
+88.78%
0.00
-22.63%
0.00
Rent Expense Supplemental
0.01
+63.83%
0.00
+88.78%
0.00
-22.63%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
7.98
-20.69%
10.07
-18.60%
12.37
+136.63%
5.23
Current Assets
3.66
-38.96%
6.00
-40.57%
10.10
+304.86%
2.49
Cash Cash Equivalents And Short Term Investments
2.10
-57.84%
4.97
-44.74%
9.00
+469.41%
1.58
Cash And Cash Equivalents
2.10
-57.84%
4.97
-44.74%
9.00
+469.41%
1.58
Cash Financial
2.10
-57.84%
4.97
-44.74%
9.00
+469.41%
1.58
Receivables
0.13
+8.95%
0.12
-40.80%
0.20
+255.58%
0.06
Accounts Receivable
0.10
+452.97%
0.02
0.00
Other Receivables
0.02
-65.45%
0.06
+374.32%
0.01
-76.89%
0.06
Taxes Receivable
0.01
+81.40%
0.00
-38.60%
0.00
Accrued Interest Receivable
0.00
-96.87%
0.04
-80.50%
0.19
Prepaid Assets
1.44
+57.89%
0.91
+1.37%
0.90
+4.70%
0.86
Total Non Current Assets
4.32
+6.27%
4.07
+78.99%
2.27
-16.87%
2.73
Net PPE
3.69
+13.48%
3.25
+57.55%
2.06
-16.57%
2.47
Gross PPE
5.90
+17.51%
5.02
+46.38%
3.43
-2.78%
3.53
Accumulated Depreciation
-2.21
-24.93%
-1.77
-29.47%
-1.36
-29.63%
-1.05
Properties
0.00
0.00
0.00
0.00
Land And Improvements
0.61
+4.01%
0.59
+57.99%
0.37
-5.74%
0.39
Buildings And Improvements
2.05
+3.02%
1.99
+87.98%
1.06
-3.17%
1.10
Machinery Furniture Equipment
0.51
+14.50%
0.45
+35.61%
0.33
-1.73%
0.34
Other Properties
2.72
+36.69%
1.99
+19.44%
1.67
-2.06%
1.70
Goodwill And Other Intangible Assets
0.12
+34.22%
0.09
+649.62%
0.01
-34.00%
0.02
Goodwill
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Other Intangible Assets
0.12
+34.35%
0.09
+668.74%
0.01
-34.66%
0.02
Investments And Advances
0.02
-91.76%
0.22
+13.27%
0.20
-18.52%
0.24
Long Term Equity Investment
0.00
-100.00%
0.22
+13.27%
0.20
-18.52%
0.24
Non Current Accounts Receivable
0.49
-2.54%
0.50
Total Liabilities Net Minority Interest
1.13
+10.48%
1.02
-8.96%
1.12
-75.76%
4.64
Current Liabilities
0.71
+16.90%
0.61
-15.39%
0.72
-82.79%
4.17
Payables And Accrued Expenses
0.44
+0.28%
0.44
-15.73%
0.52
+26.50%
0.41
Payables
0.19
+148.24%
0.08
+1.17%
0.08
-57.48%
0.18
Accounts Payable
0.12
+222.89%
0.04
+56.93%
0.02
+68.29%
0.01
Other Payable
0.06
+63.78%
0.04
-26.05%
0.05
-68.28%
0.16
Current Accrued Expenses
0.25
-30.61%
0.36
-18.57%
0.45
+89.32%
0.24
Total Tax Payable
0.00
0.00
0.00
-100.00%
0.00
Current Debt And Capital Lease Obligation
0.06
+31.65%
0.05
+14.07%
0.04
-98.92%
3.74
Current Debt
0.04
+8.49%
0.04
+10.98%
0.03
-99.09%
3.74
Other Current Borrowings
0.04
+8.49%
0.04
+10.98%
0.03
-99.09%
3.74
Current Capital Lease Obligation
0.02
+137.21%
0.01
+30.65%
0.01
-17.98%
0.01
Current Deferred Liabilities
0.18
+67.48%
0.11
+1199.40%
0.01
-7.73%
0.01
Current Deferred Revenue
0.18
+67.48%
0.11
+1199.40%
0.01
-7.73%
0.01
Other Current Liabilities
0.03
+109.83%
0.01
-91.85%
0.15
Total Non Current Liabilities Net Minority Interest
0.42
+1.15%
0.42
+2.35%
0.41
-14.25%
0.48
Long Term Debt And Capital Lease Obligation
0.42
+1.15%
0.42
+2.35%
0.41
-14.25%
0.48
Long Term Debt
0.37
-6.51%
0.39
-3.30%
0.41
-13.02%
0.47
Long Term Capital Lease Obligation
0.05
+132.16%
0.02
0.00
-100.00%
0.01
Stockholders Equity
6.54
-27.01%
8.97
-20.27%
11.25
+1815.76%
0.59
Common Stock Equity
6.54
-27.01%
8.97
-20.27%
11.25
+1815.76%
0.59
Capital Stock
24.66
+3.63%
23.79
+0.31%
23.72
+166.13%
8.91
Common Stock
24.66
+3.63%
23.79
+0.31%
23.72
+166.13%
8.91
Share Issued
11.83
+2.50%
11.54
+0.09%
11.53
+5.39%
10.94
Ordinary Shares Number
11.83
+2.50%
11.54
+0.09%
11.53
+5.39%
10.94
Retained Earnings
-18.83
-26.81%
-14.85
-20.41%
-12.33
-50.41%
-8.20
Gains Losses Not Affecting Retained Earnings
0.60
+2890.87%
0.02
+109.30%
-0.22
-70.53%
-0.13
Minority Interest
0.31
+297.72%
0.08
+8232.74%
-0.00
-40.18%
-0.00
Other Equity Adjustments
0.53
+611.84%
0.07
Total Equity Gross Minority Interest
6.85
-24.22%
9.04
-19.57%
11.24
+1817.82%
0.59
Total Capitalization
6.91
-26.14%
9.36
-19.67%
11.65
+1003.69%
1.06
Working Capital
2.95
-45.24%
5.39
-42.49%
9.38
+661.20%
-1.67
Invested Capital
6.95
-26.01%
9.40
-19.58%
11.69
+143.89%
4.79
Total Debt
0.48
+4.17%
0.46
+3.40%
0.45
-89.38%
4.22
Net Debt
2.63
Capital Lease Obligations
0.07
+133.49%
0.03
+394.78%
0.01
-56.14%
0.01
Net Tangible Assets
6.42
-27.65%
8.87
-21.01%
11.23
+1876.99%
0.57
Tangible Book Value
6.42
-27.65%
8.87
-21.01%
11.23
+1876.99%
0.57
Available For Sale Securities
0.02
Duefrom Related Parties Current
0.00
Dueto Related Parties Current
0.00
-100.00%
0.00
Foreign Currency Translation Adjustments
0.08
+245.61%
-0.05
+75.27%
-0.22
-70.53%
-0.13
Investmentin Financial Assets
0.02
0.00
Investmentsin Associatesat Cost
0.00
-100.00%
0.22
+13.27%
0.20
-18.52%
0.24
Other Equity Interest
0.11
0.07
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-3.70
-36.44%
-2.71
+23.26%
-3.53
-152.52%
-1.40
Cash Flow From Continuing Operating Activities
-3.70
-36.44%
-2.71
+23.26%
-3.53
-152.52%
-1.40
Net Income From Continuing Operations
-4.00
-58.47%
-2.52
+38.98%
-4.13
-32.04%
-3.13
Depreciation Amortization Depletion
0.40
+19.75%
0.34
-12.01%
0.38
-2.98%
0.39
Depreciation
0.37
+15.17%
0.32
-14.03%
0.37
-1.29%
0.38
Amortization Cash Flow
0.03
+131.40%
0.01
+106.36%
0.01
-51.55%
0.01
Depreciation And Amortization
0.40
+19.75%
0.34
-12.01%
0.38
-2.98%
0.39
Amortization Of Intangibles
0.03
+131.40%
0.01
+106.36%
0.01
-51.55%
0.01
Other Non Cash Items
-0.10
+65.36%
-0.30
-26.84%
-0.23
-290.48%
0.12
Stock Based Compensation
0.69
0.00
0.00
Asset Impairment Charge
0.01
0.00
0.00
-100.00%
0.00
Operating Gains Losses
-0.22
-29.05%
-0.17
-166.57%
0.25
+2075.11%
0.01
Gain Loss On Investment Securities
0.01
+109.49%
-0.14
-161.78%
0.22
Unrealized Gain Loss On Investment Securities
0.00
0.00
-100.00%
0.10
-90.94%
1.09
Net Foreign Currency Exchange Gain Loss
0.06
+460.54%
-0.02
-532.72%
-0.00
+88.30%
-0.02
Gain Loss On Sale Of PPE
0.00
0.00
+100.00%
-0.00
Change In Working Capital
-0.49
-703.74%
-0.06
-157.57%
0.10
-4.53%
0.11
Change In Receivables
-0.56
-604.74%
-0.08
-1403.92%
-0.01
+96.38%
-0.15
Change In Payables And Accrued Expense
-0.00
+99.80%
-0.08
-177.25%
0.11
-59.17%
0.27
Change In Payable
-0.00
+99.80%
-0.08
-177.25%
0.11
-59.17%
0.27
Change In Other Working Capital
0.07
-29.56%
0.10
+5140.06%
0.00
+119.54%
-0.01
Investing Cash Flow
0.93
-17.51%
1.13
+141.25%
-2.73
-476.97%
-0.47
Cash Flow From Continuing Investing Activities
0.93
-17.51%
1.13
+141.25%
-2.73
-476.97%
-0.47
Net PPE Purchase And Sale
-0.64
+54.45%
-1.40
-2301.96%
-0.06
+87.68%
-0.47
Purchase Of PPE
-0.64
+54.45%
-1.40
-2301.96%
-0.06
+87.70%
-0.47
Sale Of PPE
0.00
0.00
-100.00%
0.00
Capital Expenditure
-0.70
+52.95%
-1.49
-2463.57%
-0.06
+87.70%
-0.47
Net Investment Purchase And Sale
0.27
-89.06%
2.50
+190.14%
-2.77
0.00
Purchase Of Investment
-2.77
0.00
Sale Of Investment
0.27
-89.06%
2.50
Net Business Purchase And Sale
1.22
+671.26%
0.16
0.00
0.00
Purchase Of Business
0.00
0.00
Gain Loss On Sale Of Business
-0.29
0.00
0.00
Net Intangibles Purchase And Sale
-0.07
+30.70%
-0.09
0.00
0.00
Purchase Of Intangibles
-0.07
+30.70%
-0.09
0.00
0.00
Net Other Investing Changes
-0.02
+95.90%
-0.50
Financing Cash Flow
0.21
+421.53%
-0.06
-100.59%
10.92
+1027.25%
0.97
Cash Flow From Continuing Financing Activities
0.21
+421.53%
-0.06
-100.59%
10.92
+1027.25%
0.97
Net Issuance Payments Of Debt
-0.05
-20.10%
-0.04
+86.90%
-0.34
-164.39%
-0.13
Issuance Of Debt
0.00
0.00
-100.00%
0.30
Repayment Of Debt
-0.05
-20.10%
-0.04
+86.90%
-0.34
+20.60%
-0.43
Long Term Debt Issuance
0.00
0.00
-100.00%
0.30
Long Term Debt Payments
-0.05
-20.10%
-0.04
+86.90%
-0.34
+20.60%
-0.43
Net Long Term Debt Issuance
-0.05
-20.10%
-0.04
+86.90%
-0.34
-164.39%
-0.13
Short Term Debt Issuance
0.00
-100.00%
0.30
Short Term Debt Payments
-0.30
+14.29%
-0.35
Net Short Term Debt Issuance
-0.30
-500.00%
-0.05
Net Common Stock Issuance
0.28
0.00
-100.00%
11.31
+824.80%
1.22
Cash Dividends Paid
0.00
0.00
0.00
0.00
Net Other Financing Charges
Changes In Cash
-2.56
-55.29%
-1.65
-135.39%
4.66
+615.82%
-0.90
Effect Of Exchange Rate Changes
-0.04
-134.69%
0.12
+1003.29%
-0.01
+55.37%
-0.03
Beginning Cash Position
4.70
-24.54%
6.22
+294.01%
1.58
-37.13%
2.51
End Cash Position
2.10
-55.39%
4.70
-24.54%
6.22
+294.01%
1.58
Free Cash Flow
-4.40
-4.67%
-4.20
-17.13%
-3.59
-91.73%
-1.87
Common Stock Issuance
0.28
0.00
-100.00%
11.31
+824.80%
1.22
Earnings Losses From Equity Investments
0.01
+146.43%
-0.01
-144.12%
0.03
-7.00%
0.03
Interest Paid CFF
-0.02
-2.92%
-0.02
+56.52%
-0.05
+62.68%
-0.13
Interest Received CFI
0.16
-65.16%
0.47
+373.30%
0.10
0.00
Interest Received CFO
0.00
-100.00%
0.00
+288.76%
0.00
-70.29%
0.00
Issuance Of Capital Stock
0.28
0.00
-100.00%
11.31
+824.80%
1.22
Sale Of Business
1.22
+671.26%
0.16
0.00
Taxes Refund Paid
0.00
0.00
+100.00%
-0.00
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category